What is ATB Therapeutics?
Founded in 2017, ATB Therapeutics operates at the intersection of advanced manufacturing and oncology. The company has engineered a proprietary technology platform designed to produce a distinct class of immunotherapeutics. These assets are specifically engineered to achieve high efficacy while maintaining an unprecedented safety profile, addressing a significant unmet need in the treatment of both hematological and solid cancers.
By focusing on hard-to-treat malignancies, the company distinguishes itself through a science-first methodology. Its market position is defined by its ability to bridge the gap between complex biological engineering and clinical-grade therapeutic production, positioning it as a high-potential player in the next generation of cancer research.
How much funding has ATB Therapeutics raised?
ATB Therapeutics has raised a total of $57.2M across 1 funding round:
Series A
$57.2M
Series A (2024): $57.2M with participation from MRL Ventures Fund and EQT Life Sciences
Key Investors in ATB Therapeutics
MRL Ventures Fund
MRL Ventures Fund is a therapeutics-focused corporate venture group that partners with visionary founders to invest in early-stage, preclinical therapeutics companies globally, providing capital and strategic guidance.
EQT Life Sciences
A prominent life sciences investment firm specializing in supporting innovative healthcare and biotechnology companies through various stages of development.
What's next for ATB Therapeutics?
With the recent capital influx, ATB Therapeutics is set to prioritize the advancement of its lead assets through rigorous preclinical testing. The strategic roadmap involves scaling its manufacturing capabilities to support upcoming development milestones and expanding its research team to bolster its pipeline of oncology candidates.
The company's focus remains on de-risking its therapeutic assets, ensuring that the safety and efficacy profiles demonstrated in early research translate effectively into preclinical models. As the firm matures, it will likely seek further strategic partnerships to navigate the complexities of clinical trials and regulatory pathways, ultimately aiming to bring transformative treatments to patients suffering from aggressive cancer types.
